227 DNA clamp
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Homogeneous non-metal compounds | 15 | 6.2 | 2.44× | q = 7.9e-4 | |
| Organic oxygen compounds | 9 | 5.7 | 1.58× | q = 0.21 | |
| Homogeneous metal compounds | 14 | 14.0 | 1.00× | q = 1.00 | |
| Nucleosides, nucleotides, and analogues | 0 | 7.9 | 0 | q = 5.5e-4 | |
| Hydrocarbons | 1 | 0.2 | 5.01× | not tested | |
| Organosulfur compounds | 2 | 0.6 | 3.40× | not tested | |
| Benzenoids | 4 | 2.1 | 1.91× | not tested | |
| Organic acids and derivatives | 6 | 4.4 | 1.36× | not tested | |
| Organoheterocyclic compounds | 4 | 4.4 | 0.91× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00120 | PHE | Phenylalanine | 4 |
| DB00125 | ARG | Arginine | 4 |
| DB00149 | LEU | Leucine | 4 |
| DB00738 | PNT | Pentamidine | 4 |
| DB00861 | 1FL | Diflunisal | 4 |
| DB02967 | NEQ | N-Ethylmaleimide | 4 |
| DB06998 | 322 | [(5R)-5-(2,3-dibromo-5-ethoxy-4-hydroxybenzyl)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetic acid | 4 |
| DB00142 | GLU | Glutamic acid | 2 |
| DB00156 | THR | Threonine | 2 |
| DB00279 | T3 | Liothyronine | 2 |
| DB00945 | — | Acetylsalicylic acid | 2 |
| DB00963 | 27R | Bromfenac | 2 |
| DB02159 | PGR | (R)-Propylene glycol | 2 |
| DB03100 | 6NI | 6-Nitroindazole | 2 |
| DB07108 | 4FC | 4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID | 2 |
| DB02078 | PG5 | Triglyme | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| CAmetal | CALCIUM ION | 105 |
| CL | CHLORIDE ION | 74 |
| NAmetal | SODIUM ION | 36 |
| BR | BROMIDE ION | 18 |
| ZNmetal | ZINC ION | 16 |
| ACE | ACETYL GROUP | 10 |
| MGmetal | MAGNESIUM ION | 10 |
| IOD | IODIDE ION | 6 |
| NEQ | N-ETHYLMALEIMIDE | 6 |
| Kmetal | POTASSIUM ION | 5 |
| 0LA | (2S)-2-(6-chloro-9H-carbazol-2-yl)propanoic acid | 4 |
| 1FL | 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID | 4 |
| 2HO | 3,4-difluorobenzamide | 4 |
| 2HQ | 5-chloro-1H-indole-2,3-dione | 4 |
| 2VD | (2R)-6-bromo-9-(2-{[(1R)-1-carboxy-2-phenylethyl]amino}-2-oxoethyl)-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid | 4 |
| 2VF | (2R)-9-(2-amino-2-oxoethyl)-6-chloro-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid | 4 |
| 2VG | (2R)-6-chloro-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid | 4 |
| 2VM | (2R)-6-bromo-9-(2-{[(1S)-1-carboxy-2-phenylethyl]amino}-2-oxoethyl)-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid | 4 |
| 322 | [(5R)-5-(2,3-dibromo-5-ethoxy-4-hydroxybenzyl)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetic acid | 4 |
| 743 | (1R,5R)-5-{(1Z)-N-[(4'-fluorobiphenyl-4-yl)methoxy]butanimidoyl}-2,2-dimethyl-4,6-dioxocyclohexanecarbonitrile | 4 |